Healthcare stocks have been forgotten. Eli Lilly, McKesson, and 9 more to buy.

A few sectors have dominated the market this year, and healthcare isn’t one of them. Many stocks in the sector look ready to ...

Eli Lilly widens obesity drug lead as Zepbound, Mounjaro sales soar

Sales of Zepbound and Mounjaro soared during the second quarter, easily beating Wall Street estimates and widening the gap ...

Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street ...

Eli Lilly jumps after Q2 beat driven by obesity drugs

Eli Lilly (LLY) stock jumps as the firm posts better-than-expected Q2 2026 results, driven by its injectable GLP-1s and its ...
24/7 Wall St.

GLP-1’s Drove Eli Lilly’s Record-Breaking Q2, but AI Will Be Its Future

Eli Lilly just posted one of the most impressive quarters in pharmaceutical history, but the drug powering those numbers may ...

Eli Lilly rallies on earnings

CNBC's Annika Kim Constantino joins 'Squawk on the Street' to discuss Eli Lilly's Q2 results and why the company is ...

CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases

CVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its ...